Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. 1983

M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna

Forty-nine consecutive previously untreated patients with extensive stage small cell bronchogenic carcinoma were treated with cyclophosphamide 1,000 mg/m2, doxorubicin 50 mg/m2, etoposide (VP-16-213) 125 mg/m2, and vincristine 1.4 mg/m2 (maximum 2 mg) as induction chemotherapy. Thirty-four patients were given high-intensity therapy, receiving these drugs on both Days 1 and 8 of two or three 21-day induction courses. Fifteen other patients were treated with moderate intensity, receiving these drugs only on Day 1 of two 21-day induction courses. The number and intensity of induction courses were determined by the time of entry into the study. There were 31 complete or partial remissions among the 33 evaluable patients treated with high-intensity therapy (94 percent), including eight complete remissions (24 percent), whereas there were 11 responses (73 percent) including three complete responses (20 percent) among the 15 patients treated with moderate-intensity therapy. There was no marked tendency for the patients in the high-intensity group to have a more favorable response to the induction chemotherapy (p = 0.22), and survival experience was very similar in the two groups (p = 0.92). Overall median survival was 12 months. Within the high-intensity group, there was no significant difference between patients receiving two or three courses of induction therapy with respect to response (p = 0.97) or survival (p = 0.32). There were six induction deaths in the high-intensity induction group (18 percent) and one induction death in the moderate-intensity group (7 percent) (p = 0.59). In addition to the expected hematologic and infectious complications, there were unexpectedly high frequencies of mucositis, reversible congestive heart failure, and severe peripheral neuropathy in patients treated with high-intensity induction. Only two patients, both in the high-intensity group, were alive and free of disease at 24 months. Increasing the intensity of induction chemotherapy with these drugs did not significantly improve response or survival in extensive stage small cell bronchogenic carcinoma.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
February 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
March 1984, The American journal of medicine,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
September 1983, Cancer treatment reviews,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
August 1980, International journal of radiation oncology, biology, physics,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
January 1980, Cancer chemotherapy and pharmacology,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
January 1983, JAMA,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
January 1977, Cancer treatment reports,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
August 1980, International journal of radiation oncology, biology, physics,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
February 1983, Onkologie,
M Brower, and D C Ihde, and A Johnston-Early, and P A Bunn, and M H Cohen, and D N Carney, and R W Makuch, and M J Matthews, and P A Radice, and J D Minna
March 1983, Seminars in oncology,
Copied contents to your clipboard!